===Fulgent Genetics (FLGT) reported earnings on Thur 30 July 26 (a/h)

 

Fulgent Genetics fiscal Q2 2026 non-GAAP EPS -$0.58 on revenue $85.4M misses EPS and revenue estimates as company cuts 2026 revenue guidance to $330–340M

• Non-GAAP EPS declined 929% year over year in Q2 2026.
• Revenue increased 4% year over year in Q2 2026 period.
• 2026 revenue guidance was cut due to billing issues affecting the business.
• Therapeutics pipeline continues to advance toward Phase 3 stage of development.